Shares of Japanese pharmaceutical companies slumped in early Tokyo trading on Friday after U.S. President Donald Trump's website offering discounted prescription medicines went live. ...

2026年1月27日，湛江金融监管分局发布批复称，《关于泰康人寿保险有限责任公司广东湛江吴川支公 司变更地址的请示》(泰康粤字发〔2026〕6号)收悉。经审核，现批复如下： 二、泰康人寿保险有限责任公司应按照有关规定及时办理变更及许可证换领事宜。 一、同意泰康人寿保险有限责任公司广东湛江吴川支公司将营业场所变更为：广东省湛江市吴川市海滨 街道创业路52号华和南国茗苑1号楼11号商铺。 ...

Core Insights - Takeda Pharmaceutical Company Limited (NYSE:TAK) is identified as one of the best healthcare stocks to buy for 2026, despite facing challenges due to VYVANSE's loss of exclusivity [1][2] Financial Performance - For Q3 FY2025, Takeda reported a revenue of ¥3,411.2 billion, reflecting a year-over-year decline of 3.3% at constant exchange rates [2] - Core operating profit decreased by 3.4% to ¥971.6 billion, while reported operating profit increased by 1.2% to ¥422.4 billion [2] - Operating cash flow rose by 15.8% to ¥966.9 billion, and adjusted free cash flow increased by 10.1% to ¥625.9 billion, indicating strong cash flow management [2] Product Performance - Growth and launch products contributed positively, rising by 6.7% at constant exchange rates and now accounting for 52% of total revenue [1] - Key growth drivers included Entyvio (+7.4%), Livtencity (+43.6%), and Qdenga (+22.1%), which helped mitigate the impact of VYVANSE's significant decline of 45.7% [1] Upcoming Products - The company is preparing to launch three transformative medicines—Oveporexton, Rusfertide, and Zasocitinib—between late 2026 and early 2027, aiming to drive long-term growth [2] - Takeda is also accelerating late-stage programs in gastrointestinal, neuroscience, and oncology sectors [2] New Product Launch - On January 22, Takeda announced the U.S. launch of GAMMAGARD LIQUID ERC, an immunoglobulin therapy for primary immunodeficiency patients aged two and older, which can be administered without reconstitution [3] - The product features Enhanced Removal Capability to lower IgA levels and is available in various vial sizes, enhancing treatment options for patients [3] Company Overview - Takeda is a top-20 global, R&D-driven biopharmaceutical company headquartered in Japan, focusing on innovative medicines in oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies, and vaccines [4]

We last touched on Takeda Pharmaceutical Company Limited ( TAK ) back in May, at the end of the previous fiscal year. The stock was beaten down, and while we were expecting 2025 to be a challenge,I’m Jason Ditz and I have 20 years of experience in foreign policy research. My work has appeared in Forbes, Toronto Star, Minneapolis Star-Tribune, Providence Journal, Washington Times and the Detroit Free Press, as well as American Conservative Magazine and the Quincy Institute for Responsible Statecraft. I have ...

We last touched on Takeda Pharmaceutical Company Limited ( TAK ) back in May, at the end of the previous fiscal year. The stock was beaten down, and while we were expecting 2025 to be a challenge,I’m Jason Ditz and I have 20 years of experience in foreign policy research. My work has appeared in Forbes, Toronto Star, Minneapolis Star-Tribune, Providence Journal, Washington Times and the Detroit Free Press, as well as American Conservative Magazine and the Quincy Institute for Responsible Statecraft. I have ...

刘燕拥有逾十五年制药行业管理经验。她于2021年加入武田，历任武田中国消化事业部、血友病及罕见 病事业部负责人，并于2025年7月起担任武田中国代理总裁。在她的带领和推动下，武田中国持续加速 全球产品引入、探索创新业务模式、挖掘数字技术潜力，同时不断深化行业生态协作，坚定履行对中国 市场和患者的承诺。 1月30日，武田制药宣布任命刘燕为武田中国总裁，全面负责武田中国的整体战略和业务发展。她也同 时成为新成立的武田制药国际事业部管理委员会成员。 ...

Management updated its full-year guidance by revising revenue expectations downward at constant exchange rates, citing stronger-than-anticipated Vyvanse generic erosion in the U.S. Furuta said Takeda is “revising only revenue guidance to low single-digit decline at CER,” while maintaining full-year guidance for core operating profit and core EPS due to ongoing operating expense discipline. Based on revised FX assumptions, Takeda forecast full-year revenue of JPY 4.53 trillion, core operating profit of JPY 1 ...

Takeda Pharmaceutical Company (NYSE:TAK) Q3 2026 Earnings call January 29, 2026 05:30 AM ET Company ParticipantsAndrew Plump - President of Research & DevelopmentChristophe Weber - CEOChristopher O'Reilly - Head of Investor RelationsJulie Kim - CEO-electMilano Furuta - CFOConference Call ParticipantsHidemaru Yamaguchi - AnalystHiroyuki Matsubara - AnalystMike Nedelcovych - AnalystSeiji Wakao - AnalystShinichiro Muraoka - AnalystSteve Barker - AnalystTony Ren - AnalystChristopher O'ReillyThank you for taking ...

Takeda Pharmaceutical Company (NYSE:TAK) Q3 2026 Earnings call January 29, 2026 05:30 AM ET Company ParticipantsAndrew Plump - President of Research & DevelopmentChristophe Weber - CEOChristopher O'Reilly - Head of Investor RelationsJulie Kim - CEO-electMilano Furuta - CFONone - Company RepresentativeConference Call ParticipantsHidemaru Yamaguchi - AnalystHiroyuki Matsubara - AnalystMike Nedelcovych - AnalystSeiji Wakao - AnalystShinichiro Muraoka - AnalystSteve Barker - AnalystTony Ren - AnalystChristopher ...

Takeda Pharmaceutical Company (NYSE:TAK) Q3 2026 Earnings call January 29, 2026 05:30 AM ET Speaker2Thank you for taking time out of a very busy schedule to join us for the earnings announcement for the third quarter, FY 25 by Takeda. I'm the MC, O'Reilly, from IR. I would like to explain the language setting first. Please find the button for the language selection at the bottom of your window for the Zoom screen. If you wish to listen in Japanese, please select Japanese. If you wish to listen in English, p ...